This Phase III trial is comparing the effects of giving an oral drug (Osimertinib) alone and in combination with stereotactic radiosurgery (SRS) in patients with non-small cell lung cancer (NSCLC) that has spread to the brain.
This trial is treating patients with non-small cell lung cancer (NSCLC).
This is a systemic therapy and radiotherapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Trans Tasman Radiation Oncology Group (TROG)
In this trial, patients with EGFR mutated non-small cell lung cancer (NSCLC) will be randomised to receive oral Osimernib (80mg, taken once daily) alone or following upfront stereotactic radiosurgery (SRS).
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More